Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics director Patrick J. Heron filed an amended insider report that corrects his indirect share holdings. A prior Form 4 understated the number of common shares indirectly held through Frazier Life Sciences X, L.P. by 2,646 shares due to a scrivener's error. After this correction, 27,448 shares of common stock are reported as indirectly held. These shares are owned of record by Frazier Life Sciences X, L.P., whose general partners are affiliated entities where Heron is one of two managing members. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Arcutis Biotherapeutics director Patrick J. Heron reported new equity awards. He received 5,778 Restricted Stock Units in connection with his service as a non-employee director at the 2026 annual stockholder meeting. Each RSU converts into one share of common stock upon vesting.
The RSUs vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service, and settlement has been deferred under a prior deferral election. Heron also received a stock option for 16,667 shares at an exercise price of $21.23 per share, vesting on the same schedule and expiring on June 5, 2036.
Following these awards, he holds 32,213 shares directly, in addition to indirect interests in shares held by The Heron Living Trust and several Frazier Life Sciences entities, for which he disclaims beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics director Sue-Jean Lin reported equity awards tied to board service. She received 5,778 Restricted Stock Units as of the company’s 2026 annual stockholder meeting, bringing her direct common stock holdings to 32,513 shares after the award.
Each RSU converts into one share of common stock upon vesting, which occurs on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service. Settlement of the vested RSUs has been deferred under a prior deferral election.
Lin was also granted a stock option covering 16,667 shares of common stock at an exercise price of $21.23 per share. The option vests and becomes exercisable in full on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, contingent on continued board service through that date.
Arcutis Biotherapeutics director Howard G. Welgus received new equity awards as part of his board compensation. He acquired 5,778 Restricted Stock Units, each convertible into one share of common stock upon vesting, and a stock option for 16,667 shares at an exercise price of $21.23 per share.
The RSUs and option both vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, subject to continued service. Following the RSU grant, he directly holds 38,378 shares of common stock.
Arcutis Biotherapeutics director Leonard Keith R reported equity awards connected to his service as a non-employee director as of the company’s 2026 annual meeting. He received 5,778 Restricted Stock Units (RSUs), each convertible into one share of common stock upon vesting on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service. Settlement of the vested RSUs has been deferred under an RSU Deferral Election Form adopted on October 28, 2025. He was also granted a stock option for 16,667 shares of common stock at an exercise price of $21.23 per share, vesting on the same schedule and expiring on June 5, 2036. Following these awards, he holds 27,901 shares directly and 1,750 shares indirectly through the Leonard Family Trust dated August 28, 1996, for which he disclaims beneficial ownership except for his pecuniary interest.
Arcutis Biotherapeutics director Terrie Curran reported equity compensation grants. Curran received 5,778 Restricted Stock Units in connection with service as a non-employee director at the 2026 annual stockholder meeting, with one share of common stock issuable per RSU upon vesting. The RSUs vest on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service, and settlement has been deferred under a prior RSU deferral election. Curran was also granted options covering 16,667 shares of common stock at a $21.23 exercise price, vesting 100% on the same schedule. Following these awards, Curran directly holds 23,526 common shares.
Arcutis Biotherapeutics, Inc. director Amit Munshi reported equity awards tied to his service as a non-employee director. He received 5,778 Restricted Stock Units that convert into an equal number of common shares when they vest. After this grant, he holds 9,799 common shares directly.
Munshi also received a stock option for 16,667 shares of common stock at an exercise price of $21.23 per share. Both the RSUs and the option vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, subject to continued service through the vesting date.
Arcutis Biotherapeutics director Halley E. Gilbert reported equity awards rather than open-market trades. On June 5, 2026, Gilbert received 5,778 Restricted Stock Units (RSUs) in connection with service as a non-employee director. Each RSU will convert into one share of common stock when it vests.
The RSUs vest on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to continued service. On the same date, Gilbert was also granted a stock option for 16,667 shares of common stock at an exercise price of $21.23 per share, vesting on the same schedule. Following the RSU grant, Gilbert directly owns 27,901 shares of common stock.
Arcutis Biotherapeutics director Neha Krishnamohan received new equity awards, including restricted stock units and stock options. She was granted 5,778 RSUs and 16,667 stock options with a $21.23 exercise price per share. Both the RSUs and options vest 100% on the earlier of June 5, 2026 or immediately before the next annual stockholder meeting, subject to continued service. Following the grant, she holds 27,901 shares of common stock directly, plus the newly granted options for 16,667 underlying shares.
Arcutis Biotherapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 5, 2026. Stockholders of record as of April 8, 2026, when 125,073,249 common shares were outstanding, were entitled to vote.
All three proposals were approved. Three Class III directors were elected to serve until the 2029 annual meeting, with support ranging from about 62.8 million to 75.8 million votes for each nominee, plus broker non-votes. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
On a non-binding advisory basis, stockholders approved the compensation of the company’s named executive officers with about 88.7 million votes for, 3.7 million against, and 0.8 million abstentions. The Board also approved revisions to the Amended and Restated Non-Employee Director Compensation Program, effective as of the Annual Meeting, updating cash and equity compensation for non-employee directors.